Indian stocks: Visit www.stage2stocks.com →

Prelude Therapeutics Incorporated

Stage 3 · Topping · week 3

As of Oct 22, 2026, Prelude Therapeutics is in Stage 3, the topping phase, now in week 3 (since Oct 2, 2026). It closed at $3.60, 45.7% below its 52-week high and below its 200-day average, which is rising.

Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. More about the company

$3.60
-1.37% today
$287M · Micro cap
Market Neutral — Building

Pro read

Pro

Our read

Topping: the uptrend is tiring

Setup score

—

Momentum

Steady

Edge

—

Is PRLD early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…
Stage Cycle Timeline2023-08-16 → 2026-10-22
S4 16w
S1 13w
S4 18w
S2 46w
2023-08-162026-10-22
S1S2S3S4Setup score (0–10, dashed line at 5)
S4 16w → S1 13w → S2 9w → S3 9w → S2 9w → S3 2w → S4 18w → S1 1w → S4 11w → S1 10w → S4 5w → S1 1w → S2 46w → S3 3w → S2 7w → S3 3w current
Total tracked: 165 weeks across 16 stage runs.

PRLD among Biotechnology37th of 591 by relative strength

All 591 →
Stocks in Biotechnology ranked by relative strength, with stage and one-month change
#StockStageRS1M
1GTBPStage 2 · wk 799−22.3%
2IOVAStage 2 · wk 1899+38.8%
3SLSStage 3 · wk 499−1.5%
4MRNAStage 2 · wk 1799+11.3%
5TWSTStage 2 · wk 3999−14.5%
6KODStage 2 · wk 499+172.1%
7ERASStage 3 · wk 599+0.7%
8CLYMStage 3 · wk 399−15.8%
…37PRLDStage 3 · wk 396−16.5%
vs 52W High
-45.7%
$1.19 lo$6.63 hi
45.7% below 52W high, weakening from peak
The stock is rolling over from its 52-week high. In Stage 3 distribution, new long positions carry high risk.
Stage Maturity
Week 3
1w13w26w
Week 3, early distribution
How long this stock has been in Stage 3 distribution. Longer tops often precede deeper Stage 4 declines.
vs 200 DMA
-9.3%
200 DMA: $3.97 · rising
Stock is losing its 200 DMA. Once lost, it confirms Stage 4 risk. This is a major red flag for existing holders.
Rel Volume
0.59x
vs 50-day avg
Volume spikes on down days during Stage 3 signal distribution, with institutions exiting. Stage analysis reads that as a warning against new long positions.
Trend Health
↓
Short-term trend rolling over
Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.
1M
-16.5%
3M
-6.0%
6M
-18.2%
YTD
+31.9%
1Y
+119.5%
Scan Membership
Breakout Watch
Latest: 2024-07-22
3 appearances in last 60 days. First seen: 2022-10-07.
A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.
Recent Stage Timeline
2026-10-22S3
Wk 3 · Vol 0.59x
2026-10-21S3
Wk 3 · Vol 1.03x
2026-10-20S3
Wk 3 · Vol 0.66x
2026-10-19S3
Wk 3 · Vol 3.04x
2026-10-16S3
Wk 3 · Vol 0.93x
2026-10-15S3
Wk 2 · Vol 0.78x
2026-10-14S3
Wk 2 · Vol 0.96x
2026-10-13S3
Wk 2 · Vol 1.35x
2026-10-12S3
Wk 2 · Vol 0.39x
2026-10-09S3
Wk 2 · Vol 0.68x
2026-10-08S3
Wk 1 · Vol 0.84x
2026-10-07S3
Wk 1 · Vol 0.86x
Moving averages & range
50 DMA
$4.68
200 DMA
$3.97
52W High
$6.63
52W Low
$1.19
5D Low
$3.26
Resistance levels (recent highs)
20d High
$3.96
60d High
$6.63
120d High
$6.63
250d High
$6.63
Next resistance
+10.0%
to 20d High
ROE
-57.7%
Profit margin -269.7%
Dividend Yield
0.00%
P/B 2.8

Prelude Therapeutics: quick answers

What stage is Prelude Therapeutics in?

As of Oct 22, 2026, Prelude Therapeutics (PRLD) is in Stage 3, the topping phase. It entered Stage 3 on Oct 2, 2026 and is in week 3. What the four stages mean

Is Prelude Therapeutics in an uptrend?

Its uptrend has stalled. Prelude Therapeutics is in Stage 3, the topping phase that follows an advance. It trades 9.3% below its 200-day average, which is rising.

How far is Prelude Therapeutics from its 52-week high?

Prelude Therapeutics closed at $3.60 on Oct 22, 2026, 45.7% below its 52-week high of $6.63. Its 52-week low is $1.19.

How has Prelude Therapeutics performed over the past year?

As of Oct 22, 2026, Prelude Therapeutics is up 119.5% over the past year and up 31.9% so far in 2026.

Which sector and industry is Prelude Therapeutics in?

Prelude Therapeutics is in the Biotechnology industry, part of the Health Care sector.

About this companyHealth Care· Biotechnology

Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing JAK2V617F, a driver mutation product for the treatment of myeloproliferative neoplasms, myelofibrosis (MF), polycythemia vera, and essential thrombocythemia (ET); KAT6A for the treatment of advanced breast cancer and other solid tumors; and mutated calreticulin degrader antibody conjugates to treat MF and ET. The company has collaboration with AbCellera Biologics to discover, develop, and commercialize novel degrader antibody conjugates. Prelude Therapeutics Incorporated was incorporated in 2016 and is based in Wilmington, Delaware.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.